PLSE

PLSE

USD

Pulse Biosciences Inc Common Stock (DE)

$16.060-0.440 (-2.667%)

Echtzeitkurs

Healthcare
Medical Instruments & Supplies
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$16.500

Hoch

$16.770

Tief

$15.800

Volumen

0.11M

Unternehmensfundamentaldaten

Marktkapitalisierung

1.1B

Branche

Medical Instruments & Supplies

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.18M

Börse

NCM

Währung

USD

52-Wochen-Spanne

Tief $13.766Aktuell $16.060Hoch $25

Ähnliche Nachrichten

BusinessWire

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology

Mehr anzeigen
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
BusinessWire

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it

Mehr anzeigen
Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
BusinessWire

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical System Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology

Mehr anzeigen
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
BusinessWire

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced

Mehr anzeigen
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting